Edition:
United States

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

5.20USD
12 Dec 2017
Change (% chg)

$-0.07 (-1.33%)
Prev Close
$5.27
Open
$5.34
Day's High
$5.34
Day's Low
$4.94
Volume
11,533
Avg. Vol
10,133
52-wk High
$8.14
52-wk Low
$2.81

Chart for

About

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102,... (more)

Overall

Beta: --
Market Cap(Mil.): $87.72
Shares Outstanding(Mil.): 16.64
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.97 15.71
EPS (TTM): -- -- --
ROI: -- -11.84 31.93
ROE: -- -36.93 16.16

BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck

* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer

Oct 16 2017

BRIEF-Aeglea BioTherapeutics reports Q2 loss per share $0.47‍​

* Aeglea BioTherapeutics provides corporate update and reports second quarter 2017 financial results

Aug 09 2017

Earnings vs. Estimates